Meta Pixel

News and Announcements

Insync Funds Management Ranked Superior by SQM Research

  • Published February 19, 2020 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

SQM Research has upgraded the Insync Global Capital Aware Fund to the rating Category of “Superior” (4 Stars), and in its first review awarded the Insync Global Quality Equity Fund a “Superior” (4 Stars) Rating.

This high rating indicates that SQM believes both Insync funds “have an appreciable potential to outperform over the medium-to-long term” and that “management is of a high calibre”. A Superior Rating from SQM indicates that the funds are recommended for inclusion on approved product lists (APL’s) for financial advisers and represents a great opportunity for Insync to grow its Funds Under Management through the Managed Discretionary Account and broader financial advice segments.

In its reports, SQM said: “The Funds have displayed solid defensive characteristics in the face of equity market distress” and “the Manager’s pure stock selection skills add material value”. It also noted the strength and experience of the team, stating “the investment team have considerable experience in funds management and equity investing”.

 

 

About Insync Funds Management Pty Ltd

Insync Funds Management Pty Ltd is a Sydney-based specialist future focused global equity funds management company established in 2009 that invests in a concentrated portfolio of highly profitable global stocks that have delivered superior returns for our fund investors over a sustained period of 10 years.

Register Interest

Capital Insights
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer

In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]

Capital Insights
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts

As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.

Join over 45,000+ sophisticated investors

Join Now